{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:08:30Z","timestamp":1778486910170,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Zurich (UZH) Postdoc Grant","award":["FK-22-053"],"award-info":[{"award-number":["FK-22-053"]}]},{"name":"Moderna Global Fellowship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Progn Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>During the early stages of the COVID-19 pandemic, prediction modelling was widely used to forecast infection rates while only few studies developed models to predict individual risk of infection for Omicron and subsequent variants. For such prediction models to perform well, it is important to carefully select predictors from a comprehensive set of potential factors, including prior infection and vaccination history, individual behaviors, and immunological markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This exploratory analysis aimed to develop and compare prediction models for Omicron infection to provide an evidence base for identifying key predictors of SARS-CoV-2 infections which can be used to inform future derivation and validation of predictive models. We used data from 710 participants from two ongoing, prospective population-based cohorts: the Zurich SARS-CoV-2 Cohort and the Zurich SARS-CoV-2 Vaccine Cohort (Switzerland). Participants were recruited between 2020 and 2021 and provided demographic data, vaccination history, self-reported infections, and longitudinal serological data (anti-S IgG, anti-S IgA, anti-N IgG antibodies) collected at 6-month intervals. Our main outcome was SARS-CoV-2 infection during the first Omicron wave (01.01.2022\u201331.03.2022) based on self-reported positive tests or a doubling in any of anti-S IgG, anti-S IgA or anti-N IgG. We used logistic regression models with backward stepwise selection based on the Akaike Information Criterion (AIC) to evaluate predictors and identify the best-fitting models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Only 17.3% of participants reported a positive SARS-CoV-2 test result during the Omicron wave. However, when including serological testing, 37.2% of participants had evidence of infection, indicating substantial underdiagnosis. The best-performing model had an AUC of 0.69 (95%CI 0.66, 0.73) and included the following predictors: age, sex, compliance with COVID-19 prevention guidelines, smoking status, comorbidities, prior anti-N IgG antibody levels, and the sequence of previous infections and vaccinations. We found that older age (\u2265\u200965 years) was associated with a 50\u201360% lower odds of Omicron infection across all our models, while having fewer prior exposures (through infections or vaccinations) increased the odds of infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This explorative study highlights the importance of integrating comprehensive immunological, clinical and behavioral data to predict SARS-CoV-2 infection risk. Our study lays the foundation to develop and validate future prediction models that identify individuals at risk, particularly through the novel use of infection and prior vaccination sequence as an important predictor.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41512-026-00231-0","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T07:14:46Z","timestamp":1778483686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Variable selection for prediction models of Omicron infection: Insights from two population-based cohort studies"],"prefix":"10.1186","volume":"10","author":[{"given":"Joanne","family":"Lacy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Menges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tala","family":"Ballouz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Frei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Pellaton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Fenwick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Pantaleo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milo A.","family":"Puhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"231_CR1","doi-asserted-by":"crossref","unstructured":"Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E et al. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. BMJ. 2020;369:29. Available from: https:\/\/www.bmj.com\/content\/369\/bmj.m1328. Cited 29 2024.","DOI":"10.1136\/bmj.m1328"},{"key":"231_CR2","doi-asserted-by":"crossref","unstructured":"Yan L, Zhang HT, Goncalves J, Xiao Y, Wang M, Guo Y et al. An interpretable mortality prediction model for COVID-19 patients. Nature Machine Intelligence 2020 2:5. 2020;2(5):283\u20138. Available from: https:\/\/www.nature.com\/articles\/s42256-020-0180-7. Cited 13 Aug 2024.","DOI":"10.1038\/s42256-020-0180-7"},{"key":"231_CR3","doi-asserted-by":"crossref","unstructured":"Zhao Z, Chen A, Hou W, Graham JM, Li H, Richman PS et al. Prediction model and risk scores of ICU admission and mortality in COVID-19. PLoS One. 2020;15(7):e0236618. Available from: https:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0236618. Cited 13 Aug 2024.","DOI":"10.1371\/journal.pone.0236618"},{"issue":"4","key":"231_CR4","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.chest.2020.05.580","volume":"158","author":"L Jehi","year":"2020","unstructured":"Jehi L, Ji X, Milinovich A, Erzurum S, Rubin BP, Gordon S, et al. Individualizing Risk Prediction for Positive Coronavirus Disease 2019 Testing: Results From 11,672 Patients. Chest. 2020;158(4):1364\u201375.","journal-title":"Chest"},{"key":"231_CR5","doi-asserted-by":"publisher","unstructured":"Gong J, Ou J, Qiu X, Jie Y, Chen Y, Yuan L et al. A Tool for Early Prediction of Severe Coronavirus Disease 2019 (COVID-19): A Multicenter Study Using the Risk Nomogram in Wuhan and Guangdong, China. Clinical Infectious Diseases. 2020;71(15):833\u201340. Available from: https:\/\/doi.org\/10.1093\/cid\/ciaa443. Cited 13 Aug 2024.","DOI":"10.1093\/cid\/ciaa443"},{"key":"231_CR6","doi-asserted-by":"crossref","unstructured":"Hoertel N, Blachier M, Blanco C, Olfson M, Massetti M, Rico MS et al. A stochastic agent-based model of the SARS-CoV-2 epidemic in France. Nature Medicine 2020 26:9. 2020;26(9):1417\u201321. Available from: https:\/\/www.nature.com\/articles\/s41591-020-1001-6. Cited 13 Aug 2024.","DOI":"10.1038\/s41591-020-1001-6"},{"key":"231_CR7","doi-asserted-by":"crossref","unstructured":"Menni C, Valdes AM, Freidin MB, Sudre CH, Nguyen LH, Drew DA et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nature Medicine 2020 26:7. 2020;26(7):1037\u201340. Available from: https:\/\/www.nature.com\/articles\/s41591-020-0916-2. Cited 14 Aug 2024.","DOI":"10.1038\/s41591-020-0916-2"},{"key":"231_CR8","doi-asserted-by":"crossref","unstructured":"Drew DA, Nguyen LH, Steves CJ, Menni C, Freydin M, Varsavsky T et al. Rapid implementation of mobile technology for real-time epidemiology of COVID-19. Science. 2020;368(6497):1362\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32371477\/. Cited 14 Aug 2024.","DOI":"10.1126\/science.abc0473"},{"key":"231_CR9","doi-asserted-by":"publisher","first-page":"101798","DOI":"10.1016\/j.pmedr.2022.101798","volume":"27","author":"A Ram\u00edrez Varela","year":"2022","unstructured":"Ram\u00edrez Varela A, Moreno L\u00f3pez S, Contreras-Arrieta S, Tamayo-Cabeza G, Restrepo-Restrepo S, Sarmiento-Barbieri I, et al. Prediction of SARS-CoV-2 infection with a Symptoms-Based model to aid public health decision making in Latin America and other low and middle income settings. Prev Med Rep. 2022;27:101798.","journal-title":"Prev Med Rep"},{"key":"231_CR10","unstructured":"Lehmann J, Giesinger JM, Rumpold G, Borena W, Knabl L, Falkensammer B et al. Estimating seroprevalence of SARS-CoV-2 antibodies using three self-reported symptoms: development of a prediction model based on data from Ischgl, Austria. Epidemiol Infect. 2021;149:e52. Available from: https:\/\/www.cambridge.org\/core\/journals\/epidemiology-and-infection\/article\/estimating-seroprevalence-of-sarscov2-antibodies-using-three-selfreported-symptoms-development-of-a-prediction-model-based-on-data-from-ischgl-austria\/734CF75E4555B1F730350EDCD7D4D9F7. Cited 28 Aug 2024."},{"key":"231_CR11","doi-asserted-by":"crossref","unstructured":"Zoabi Y, Deri-Rozov S, Shomron N. Machine learning-based prediction of COVID-19 diagnosis based on symptoms. npj Digital Medicine 2021 4:1. 2021;4(1):1\u20135. Available from: https:\/\/www.nature.com\/articles\/s41746-020-00372-6. Cited 28 Aug 2024.","DOI":"10.1038\/s41746-020-00372-6"},{"key":"231_CR12","doi-asserted-by":"publisher","unstructured":"Desantis SM, Yaseen A, Hao T, Le\u00f3n-Novelo L, Talebi Y, Valerio-Shewmaker MA et al. Incidence and Predictors of Breakthrough and Severe Breakthrough Infections of SARS-CoV-2 After Primary Series Vaccination in Adults: A Population-Based Survey of 22 575 Participants. J Infect Dis. 2023;227(10):1164\u201372. Available from: https:\/\/doi.org\/10.1093\/infdis\/jiad020. Cited 28 Aug 2024.","DOI":"10.1093\/infdis\/jiad020"},{"key":"231_CR13","doi-asserted-by":"crossref","unstructured":"Flacco ME, Acuti Martellucci C, Soldato G, Di Martino G, Rosso A, Carota R et al. Predictors of SARS-CoV-2 Infection and Severe and Lethal COVID-19 after Three Years of Follow-Up: A Population-Wide Study. Viruses. 2023;15(9):1794. Available from: https:\/\/www.mdpi.com\/1999-4915\/15\/9\/1794\/htm. Cited 28 Aug 2024.","DOI":"10.3390\/v15091794"},{"key":"231_CR14","doi-asserted-by":"crossref","unstructured":"B BF SG et al. T E, O L, A B, E L,. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study. PLoS Med. 2022;19(11). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36342956\/. Cited 21 Mar 2024.","DOI":"10.1371\/journal.pmed.1004125"},{"key":"231_CR15","doi-asserted-by":"crossref","unstructured":"Steyerberg EW, Moons KGM, van der Windt DA, Hayden JA, Perel P, Schroter S et al. Prognosis Research Strategy (PROGRESS) 3: Prognostic Model Research. PLoS Med. 2013;10(2):e1001381. Available from: https:\/\/journals.plos.org\/plosmedicine\/article?id=10.1371\/journal.pmed.1001381. Cited 24 Sep 2024.","DOI":"10.1371\/journal.pmed.1001381"},{"key":"231_CR16","doi-asserted-by":"crossref","unstructured":"Ballouz T, Menges D, Anagnostopoulos A, Domenghino A, Aschmann HE, Frei A et al. Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study. BMJ. 2023;381. Available from: https:\/\/www.bmj.com\/content\/381\/bmj-2022-074425. Cited 12 Nov 2024.","DOI":"10.1136\/bmj-2022-074425"},{"key":"231_CR17","doi-asserted-by":"crossref","unstructured":"Menges D, Ballouz T, Anagnostopoulos A, Aschmann HE, Domenghino A, Fehr JS et al. Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study. PLoS One. 2021;16(7):e0254523. Available from: https:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0254523. Cited 12 Nov 2024.","DOI":"10.1371\/journal.pone.0254523"},{"key":"231_CR18","doi-asserted-by":"crossref","unstructured":"B\u00fcrzle O, Menges D, Maier JD, Schams D, Puhan MA, Fehr J et al. Adverse effects, perceptions and attitudes related to BNT162b2, mRNA-1273 or JNJ-78436735 SARS-CoV-2 vaccines: Population-based cohort. npj Vaccines 2023 8:1. 2023;8(1):1\u201310. Available from: https:\/\/www.nature.com\/articles\/s41541-023-00657-3. Cited 12 Nov 2024.","DOI":"10.1038\/s41541-023-00657-3"},{"key":"231_CR19","doi-asserted-by":"crossref","unstructured":"Menges D, Zens KD, Ballouz T, Caduff N, Llanas-Cornejo D, Aschmann HE et al. Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort. Nature Communications 2022 13:1. 2022;13(1):1\u201316. Available from: https:\/\/www.nature.com\/articles\/s41467-022-32573-w. Cited 10 May 2024.","DOI":"10.1038\/s41467-022-32573-w"},{"key":"231_CR20","doi-asserted-by":"crossref","unstructured":"Cavanaugh JE, Neath AA. The Akaike information criterion: Background, derivation, properties, application, interpretation, and refinements. Wiley Interdiscip Rev Comput Stat. 2019;11(3):e1460. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/wics.1460. Cited 14 Nov 2024.","DOI":"10.1002\/wics.1460"},{"key":"231_CR21","doi-asserted-by":"crossref","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837\u201345. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/3203132\/. Cited 23 Jan 2026.","DOI":"10.2307\/2531595"},{"key":"231_CR22","doi-asserted-by":"publisher","first-page":"1178167","DOI":"10.3389\/fpubh.2023.1178167","volume":"11","author":"M Harris","year":"2023","unstructured":"Harris M, Hart J, Bhattacharya O, Russell FM. Risk factors for SARS-CoV-2 infection during the early stages of the COVID-19 pandemic: a systematic literature review. Front Public Health. 2023;11:1178167.","journal-title":"Front Public Health"},{"key":"231_CR23","doi-asserted-by":"crossref","unstructured":"Amati R, Frei A, Kaufmann M, Sabatini S, Pellaton C, Fehr J et al. Functional immunity against SARS-CoV-2 in the general population after a booster campaign and the Delta and Omicron waves, Switzerland, March 2022. Eurosurveillance. 2022;27(31):2200561. Available from: https:\/\/www.eurosurveillance.org\/content\/10.2807\/1560-7917.ES.2022.27.31.2200561. Cited 14 Aug 2024.","DOI":"10.2807\/1560-7917.ES.2022.27.31.2200561"},{"key":"231_CR24","doi-asserted-by":"crossref","unstructured":"Cohen D, Izak M, Stoyanov E, Mandelboim M, Perlman S, Amir Y et al. Predictors of reinfection with pre-Omicron and Omicron variants of concern among individuals who recovered from COVID-19 in the first year of the pandemic. Int J Infect Dis. 2023;132:72\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37072052\/. Cited 19 Nov 2024.","DOI":"10.1016\/j.ijid.2023.04.395"},{"key":"231_CR25","doi-asserted-by":"crossref","unstructured":"Dowell AC, Waiblinger D, Wright J, Ladhani SN, Moss P. Nucleocapsid-specific antibodies as a correlate of protection against SARS-CoV-2 reinfection in children. J Infect. 2023;87(3):267\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37391077\/. Cited 19 Nov 2024.","DOI":"10.1016\/j.jinf.2023.06.018"},{"key":"231_CR26","doi-asserted-by":"crossref","unstructured":"Rodda LB, Morawski PA, Pruner KB, Fahning ML, Howard CA, Franko N et al. Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity. Cell. 2022;185(9):1588\u20131601.e14. Available from: http:\/\/www.cell.com\/article\/S0092867422003282\/fulltext. Cited 14 Sep 2023.","DOI":"10.1016\/j.cell.2022.03.018"},{"key":"231_CR27","doi-asserted-by":"crossref","unstructured":"Park YJ, Pinto D, Walls AC, Liu Z, De Marco A, Benigni F et al. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. Science. 2022;378(6620):619\u201327. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36264829\/. Cited 14 Sep 2023.","DOI":"10.1126\/science.adc9127"},{"key":"231_CR28","doi-asserted-by":"crossref","unstructured":"Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis. 2023;23(5):556\u201367. Available from: http:\/\/www.thelancet.com\/article\/S1473309922008015\/fulltext. Cited 28 Aug 2024.","DOI":"10.1016\/S1473-3099(22)00801-5"},{"key":"231_CR29","doi-asserted-by":"crossref","unstructured":"Gilboa M, Gonen T, Barda N, Cohn S, Indenbaum V, Weiss-Ottolenghi Y et al. Factors Associated With Protection From SARS-CoV-2 Omicron Variant Infection and Disease Among Vaccinated Health Care Workers in Israel. JAMA Netw Open. 2023;6(5):e2314757\u2013e2314757. Available from: https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2805172. Cited 19 Nov 2024.","DOI":"10.1001\/jamanetworkopen.2023.14757"},{"key":"231_CR30","doi-asserted-by":"crossref","unstructured":"Echevarria FM, Caputo M, Camp D, Reddy S, Achenbach CJ. Incidence and risk factors of SARS-CoV-2 breakthrough infection in the early Omicron variant era among vaccinated and boosted individuals in Chicago. PLoS One. 2024;19(8):e0302338. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11299831\/. Cited 19 Nov 2024.","DOI":"10.1371\/journal.pone.0302338"},{"key":"231_CR31","doi-asserted-by":"crossref","unstructured":"Walmsley S, Nabipoor M, Lovblom LE, Ravindran R, Colwill K, McGeer A et al. Predictors of Breakthrough SARS-CoV-2 Infection after Vaccination. Vaccines. 2024, Vol 12, Page 36. 2023;12(1):36. Available from: https:\/\/www.mdpi.com\/2076-393X\/12\/1\/36\/htm. Cited 19 Nov 2024.","DOI":"10.3390\/vaccines12010036"},{"key":"231_CR32","unstructured":"Reynolds CJ, Pade C, Gibbons JM, Otter AD, Lin KM, Sandoval DM et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science. 2022;377(6603). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35699621\/. Cited 14 Sep 2023."},{"key":"231_CR33","doi-asserted-by":"crossref","unstructured":"Efthimiou O, Seo M, Chalkou K, Debray T, Egger M, Salanti G. Developing clinical prediction models: a step-by-step guide. BMJ. 2024;386:e078276. Available from: https:\/\/www.bmj.com\/content\/386\/bmj-2023-078276. Cited 19 Nov 2024.","DOI":"10.1136\/bmj-2023-078276"}],"container-title":["Diagnostic and Prognostic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41512-026-00231-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41512-026-00231-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41512-026-00231-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T07:15:06Z","timestamp":1778483706000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41512-026-00231-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["231"],"URL":"https:\/\/doi.org\/10.1186\/s41512-026-00231-0","relation":{},"ISSN":["2397-7523"],"issn-type":[{"value":"2397-7523","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"6 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all participants in the Zurich SARS-CoV-2 Cohort and the Zurich SARS-CoV-2 Vaccine Cohort. The study protocol of the Zurich SARS-CoV-2 Cohort was approved by the Cantonal Ethics Committee of Zurich (BASEC No. 2020\u2009\u2212\u200901739) and prospectively registered on the International Standard Randomized Controlled Trial Number Registry (ISRCTN 14990068, registration date: 22\/07\/2020). The study protocol of the Zurich SARS-CoV-2 Vaccine Cohort was prospectively registered (ISRCTN 15499304, registration date: 19\/03\/2021) and approved by the Cantonal Ethics Committee of Zurich (BASEC No. 2021\u2009\u2212\u200900273).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}